Value Plus

Arihant's Value Plus - February 2018



Market Outlook February: Going ahead, Indian equity markets will remain volatile as budget failed to cheer Dalal Street on the imposition of long-term capital gains (LTCG) tax of 10% on sale of equity shares. The RBI’s monetary policy will be the major event this month. The RBI’s monetary policy will be announced on February 7, 2018. Further, US FOMC meeting minutes, BOE monetary policy, Q3FY18 corporate earnings, macroeconomic data, FIIs and DIIs trend, currency movement and crude oil price movement are the key factors to watch out for. We suggest investors to invest in fundamentally sound companies with long term view.

In this issue:

  • Movers & Shakers
  • Market Outlook
  • Technical Outlook
  • Union Budget 2018-19
  • Fundamental Pick
  • Commodity Outlook
  • Mutual Fund
  • Key Financial Events – Feb

Nifty Technical Outlook February: On the monthly chart we have seen a rally of 766 points and prices have formed strong bull candle but daily chart is not supporting bulls as well as RSI also not giving confidence for further rally. So according to this two pattern combination 11200 will be major resistance for Nifty, only above that we can see momentum can continue up to 11398 – 11621 – 11882 levels. However, if Nifty trades below 11009 then it is likely to test 10657 – 10434 – 10173 levels.

Broadly, we are of the opinion that unless Nifty doesn’t cross 11200 levels for current month there is a probability that we can see some consolidation with some profit booking.


Tags: Key EventsMutual FundMovers & ShakersAuto SectorCommodity OutlookMarket OutlookNifty Technical OutlookFundamental PickUnion Budget 2018


Arihant's February Investment Newsletter is now available #‎ValuePlus
Click here to go through our flipbook now.
Click here to download full pdf report.

Search Reports

SEARCH

Reports

Daily Currency Market...

HIGHLIGHTS: The dollar index...

Read More

DFXCFSDF

SDFD

Read More

Daily Market Update...

On 22/10/2018 markets opened...

Read More

Daily Metal & Agro Buzz:

HIGHLIGHTS: The dollar...

Read More

Daily Market Update...

Sensex ended with a net loss...

Read More

GAIL

SHORT TERM TRADING CALL: BUY...

Read More

HAVELLS

SHORT TERM TRADING CALL: BUY...

Read More

CESC

SHORT TERM TRADING CALL: BUY...

Read More

ICICIBANK

SHORT TERM TRADING CALL: BUY...

Read More

Suven Life Science

Company Overview SVLS (Suven...

Read More

Subscribe to newsletter

Request a call back

DISCLAIMER: This document has been prepared by Arihant Capital Markets Limited (hereinafter called as Arihant) and its subsidiaries and associated companies. This document does not constitute an offer or solicitation for the purchase and sale of any financial instrument by Arihant. This document has been prepared and issued on the basis of publicly available information, internally developed data and other sources believed to be reliable. Whilst meticulous care has been taken to ensure that the facts stated are accurate and opinions given are fair and reasonable, neither the analyst nor any employee of our company is in any way is responsible for its contents and nor is its accuracy or completeness guaranteed. This document is prepared for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. All recipients of this material should before dealing and or transacting in any of the products referred to in this material make their own investigation, seek appropriate professional advice. The investments discussed in this material may not be suitable for all investors. The recipient alone shall be fully responsible/are liable for any decision taken on the basis of this material. Arihant Capital Markets Ltd (including its affiliates) or its officers, directors, personnel and employees, including persons involved in the preparation or issuance of this material may; (a) from time to time, have positions in, and buy or sell or (b) be engaged in any other transaction and earn brokerage or other compensation in the financial instruments/products discussed herein or act as advisor or lender/borrower in respect of such securities/financial instruments/products or have other potential conflict of interest with respect to any recommendation and related information and opinions.